

CURRICULUM VITAE

Name: Nancy M. Gardner
FKA: Roehnelt

Email: NGardner@thyroidflorida.com

CURRENT NURSING REGISTRATION (s): Florida License ARNP
ANCC Nationally Board Certification

Certification: Genetics

EDUCATION

<u>Institution</u>	<u>Degree</u>	<u>Date</u>	<u>Major</u>
NIH - NINR	Post-Doctoral	2004	Fellowship
Georgetown University	Certificate	2004	Molecular Genetics minor-
University of South Florida Tampa, Florida	PhD	2003	Public Health Clinical Epidemiology
University of South Florida Tampa, Florida	MS	1998	Nursing - Adult Advanced Nurse Practitioner

PROFESSIONAL EXPERIENCE

<u>Title of Position</u>	<u>Institution</u>	<u>Date</u>
Adult Nurse Practitioner	Thyroid & Endocrine Center of Florida, Sarasota, Florida	2019 - present
Adult Nurse Practitioner	H. Lee Moffitt Cancer Center Tampa, Florida	2010 - 2019
Online Instructor	College of Nursing Rutgers, The State University Of New Jersey, Newark, New Jersey	2010 –2013
Assistant Professor	College of Nursing Rutgers, the State University Of New Jersey, Newark, New Jersey	2005-2010
Adult Nurse Practitioner	H Lee Moffitt Cancer Center Tampa, Florida	1999-2005
	H Lee Moffitt Cancer Center Tampa, Florida	
Professor Academic appointments	College of Nursing Nursing College Medicine Dept. of Interdisciplinary Oncology & Internal Medicine University of South Florida Tampa, Florida	2004-2005
Adjunct Professor	University of South Florida College of Public Health Tampa, Florida	2000-2001
Nurse Researcher	J. Haley VA Hospital Patient Safety Research Center Tampa, Florida	1999-2000
Clinical Nursing Instructor	University of South Florida College of Nursing Tampa, Florida	1998-1999
Clinical Practice	University of South Florida Cardiology	1997-1998
	University of South Florida Family Medicine	1996-1997

Publications

Roehnelt, N (2012) Update on the Management of Neuroendocrine Tumors: Focus on Somatostatin Antitumor Effects. *Oncology Nursing Journal*, Vol.16,1: February 2012.

Gardner, N (2009) Targeting the mTOR Pathway in Neuroendocrine Tumors, *Oncology Nursing Journal*, Vol. 13, 5:October 2009.

Strosberg J., Gardner N., Kvols L. (2009) Survival and Prognostic Factor Analysis of 146 Metastatic Neuroendocrine Tumors of the Mid-Gut. *Neuroendocrinology*, Jan 28, 2009. {Epub ahead of print}

Strosberg J., Gardner N., Kvols L. Pancreas (2008) Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. *Pancreas*, Dec 5 2008. {Epub ahead of print}

Nasir, A, Gardner N, Strosberg J, et. al. (2008)_Multimodality approach to the management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum VIP and calcitonin levels. *Pancreas*. Apr; 36(3).

Strosberg J, Nasir,A , Gardner N, et. al. (2008) Metastatic carcinoid tumor to the ovary: A clinico-pathologic analysis of seventeen cases. *Gynecol Oncol*. Jul;106 (1):65-8.

Strosberg J, Hoffe S, Gardner N, Choi J, Kvols L (2007)._Effective treatment of locally advanced neuroendocrine tumors of the pancreas with chemo-radio therapy". *Neuroendocrinology*, Vol. 85, No. 4: 216 – 220.

Zesiewicz TA, Cimino CR, Malek AR, Gardner N, Leaverton PL, Dunne PB, Hauser RA (2002) Driving safety in parkinson's disease. *Neurology*. Dec10;59(11):1787-8

Leaverton PL, Schockin D, & Gardner N (1999)_Epidemiology of Cardiovascular Disease. *Mahidol University Journal*.

Abstracts only

Gardner N, Foulis P, & Kvols L (2002) The influence of somatostatin analog on serum chromogranin A and progression of disease among patients with Neuroendocrine Carcinoma, Carcinoid type: descriptive study. *British Journal of Cancer*. Vol. 86, Supplement 1, Page S116

BOOK CHAPTERS AUTHORED:

Roehnelt, N (2016). *Mosby's Oncology Nursing Advisor*, (2nd.ed) Chapter Neuroendocrine Tumors. Oncology Nursing Society

Roehnelt, N (2015). *Mosby's Oncology Nursing Textbook*. (ed. ?) Chapter 3 Pathophysiology of Head and Neck Cancer. Oncology Nursing Society. Information incomplete

Gardner N, Kvols L (2006). *Everyone's Guide for Cancer Therapy*. (5th ed.). In E H. Rosenbaum, M. Dollinger, & C\G Cable. (Eds.). *Carcinoid of the Gastrointestinal Tract* (pp. 391-396). Kansas Missouri: Andrews McMeel Publishing.

Gardner N, Coleman D (2005). An Evidence-Based Approach to the Treatment and Care of the Older Adult With Cancer (1st ed.), D. Cope & A Reb (Eds). Symptom Management of Diarrhea and Constipation (Chapter 17). Oncology Nursing Society Publisher

Presentations

- Moffitt Cancer Center Grand Rounds – Managing Immunotherapy
Endocrinopathies: 2018 NCCN Guidelines 2018
- Moffitt Cancer Center Grand Rounds - Incidental thyroid nodule,
Risk for cancer: An evaluation based on ATA criteria 2017
- University of Pittsburgh Cancer Institute (NCI-CCC),
“Therapeutic Options for Pancreatic Neuroendocrine Tumors” 2012
- University of South Florida Distinguished Lecture Series “A Pilot Study to
Investigate Germ-Line MEN1 and SDHD Mutations in Familial Carcinoid Cases” 2011
- Oncology Nursing Society Institute of Learning Conference 2008
“Carcinoid Neuroendocrine Tumors, Update on management of
carcinoid syndrome”
- North American Neuroendocrine Tumor Society (NANETs) Annual Conference 2008
“Neuroendocrine Team Coordination in the effective management of
neuroendocrine cancer patients care”

Posters

- Oncology Nursing Society Congress, “Nursing Implications for mTOR
Inhibitors in NETs” – Author 2008
- North American Neuroendocrine tumor Society (NANETs) Annual Conference 2008
Novel progression associated genes in primary pancreatic endocrine tumors
Co-author
- Clinicopathologic analysis of well, moderately and poorly differentiated metastatic
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) co-author 2008
- GI Conference at MD Anderson Neuroendocrine Tumor Meeting 2007
“Survival Analysis of 150 Metastatic Mid-Gut Carcinoid Tumors” - poster
- Deployment of B-Type Natriuretic Peptide (BNP) At a Multi-Site Facility 2004
Poster: ASCP Annual Meeting - San Antonio, Texas
- “The influence of somatostatin analog on serum Chromogranin A and progression
of disease among patients with Neuroendocrine Carcinoma, Carcinoid type: A Descriptive
study” British Cancer Research Meeting 2003

“Phase I Clinical Study SMT 487 B151 Radiolabled Octreotide, Receptor Targeted Therapy:
 OcteoTher™ –American Society Clinical Oncologist co-author 2002

Funding/Grants

2012	Neuroendocrine Foundation Primary Investigator A pilot study to investigate for germ-line mutations in a family with multiple generation first degree relative cases of carcinoid cancer using whole genome sequencing.	Grant \$25,000
2008-2010	State of New Jersey – BUSH Bio-Medical Research Grant Primary Investigator A study to investigate germ-line MEN1 and SDHD gene Mutation in familial cases of carcinoid cancer	\$20,000
2008-2009	Robert Woods Johnson Foundation: Oncology Nurse Research Scholar Grant “Professional Development though nursing scholarship and Research” – Individual award	\$21,000
2008	Rutgers Dean’s Research Grant – Principle Investigator A study to investigate germ-line MEN1 And SDHD gene Mutation in familial cases of carcinoid cancer	\$10,000
2007-2008	Robert Woods Johnson Foundation: Oncology Nursing Research Scholar Grant “Professional Development through nursing scholarship and research” – Individual award	\$16,000
2005-2006	Robert Woods Johnson Foundation: Oncology Nurse Research Scholar Grant “Professional Development through nursing scholarship and research” – individual award	\$25,000
2004	NIH Individual Intramural Training Grant Genetics Research Methods	\$20,000
2002	Novartis Pharmaceuticals The influence of somatostatin analog on serum Chromogranin A and progression of disease among patients with Neuroendocrine Carcinoid Tumors Completed project – published in British Journal of Cancer	\$5,000

Research

“A pilot study to investigate for germ-line mutations using whole genome sequencing in a family with multiple generation first degree relative cases of Small intestinal carcinoid cancer” funded- completed	2012
“A pilot study to investigate germ-line MEN1 and SDHD gene mutation in Familial cases of carcinoid cancer” funded – completed	2008-2010
“Familial carcinoid tumors of the small intestine”: Are there Germ line DNA abnormalities associated with familial cases. Funded - completed	2007-2008
“Metastasis-associated Genes and Proteins in Pancreatic Endocrine Tumors: Discovery of potential biomarkers for metastatic assay development Neuroendocrine Foundation funded- completed	2007
Retrospective Analysis of 150 cases of Small Intestinal Carcinoid: Predictive Factors Associated with Survival – completed	2007
Clinical features of retro-orbital carcinoid metastases (ROCM) Cases series-primary investigator – completed	2006
Describing the long term outcome of chemo-radiation treatment for locally Advanced neuroendocrine Tumors of the Pancreas – co-investigator- completed	2006
Deployment of B-Type Natruretic Peptide (BNP) at a Multi-Site Facility, - Co-investigator - completed	2004
Development of a predictive model for tumor response in Neuroendocrine Carcinoid patients using prognostic factors – Principal investigator Completed	2003
The influence of somatostatin analog on serum chromogranin A and progression of disease among patients with neuroendocrine carcinoma, Carcinoid type: A descriptive study – Principal investigator – completed	2002
Parkinson Disease and Driving Safety Study – Epidemiologist completed	2001
Fall Intervention Study – Epidemiologist - completed	1999

Other Activities / Appointments

Editor	Oncology Nursing Society Special Interest Newsletter for Genetics	2009-2010
Council for NP/PA	Professional Development Research Chairperson-H. Lee Moffitt Cancer Center	2006-2007
Member/Researcher	Cancer Institute of New Jersey – New Brunswick NJ Population Science Research Program Epidemiologist	2005-2008
Advisor	Oncology Medical Division, Princeton, NJ IPG/Lowe Company–Interlink Healthcare Communications	2005-2007
Consultant	RJO Company – Cardinal Health Communication, Meniscus	2002-2005
Faculty Advisor/ Speaker	Sanofi – Oxaliplatin-Colorectal Ca.	2002-2004
Key Opinion Leader	Novartis – Oncology – Sandostatin	2001-2007
Faculty/Expert	Novartis-Molecular Targeted Compound	2003-2007
Panel Member	Roche Pharmaceutical-Xeloda-Colorectal Ca.	2002-2003
Faculty/Expert	Treatment of the Malignant Carcinoid Syndrome	2003-present
Panel Member	Evidence Based Practice National Advisory Board – Oncology Nursing Society	2002-2003
Panel Member	Roche Pharmaceutical – Advisory Board Colorectal Ca	2002-2003
Council Member	University Research Council	1996-1998

Professional Associations

American Thyroid Association
Genetic Epidemiology
American Heart Association
American Association of Nurse Practitioners
American Nurses Association
Oncology Nursing Society
American Society of Clinical Oncology